X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Fulford India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA FULFORD INDIA AJANTA PHARMA/
FULFORD INDIA
 
P/E (TTM) x 25.0 398.8 6.3% View Chart
P/BV x 10.3 6.2 165.8% View Chart
Dividend Yield % 0.6 0.1 688.1%  

Financials

 AJANTA PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
FULFORD INDIA
Mar-14
AJANTA PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs1,720942 182.6%   
Low Rs1,103450 245.1%   
Sales per share (Unadj.) Rs194.6691.4 28.1%  
Earnings per share (Unadj.) Rs45.211.5 394.5%  
Cash flow per share (Unadj.) Rs50.315.4 327.5%  
Dividends per share (Unadj.) Rs8.002.00 400.0%  
Dividend yield (eoy) %0.60.3 197.2%  
Book value per share (Unadj.) Rs132.0380.0 34.7%  
Shares outstanding (eoy) m88.773.90 2,276.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.31.0 720.5%   
Avg P/E ratio x31.260.7 51.4%  
P/CF ratio (eoy) x28.145.3 61.9%  
Price / Book Value ratio x10.71.8 583.7%  
Dividend payout %17.717.4 101.4%   
Avg Mkt Cap Rs m125,2992,714 4,616.1%   
No. of employees `000NA0.4 0.0%   
Total wages/salary Rs m2,570505 508.9%   
Avg. sales/employee Rs ThNM6,073.0-  
Avg. wages/employee Rs ThNM1,137.4-  
Avg. net profit/employee Rs ThNM100.7-  
INCOME DATA
Net Sales Rs m17,2752,696 640.7%  
Other income Rs m166125 132.6%   
Total revenues Rs m17,4422,822 618.1%   
Gross profit Rs m5,807-46 -12,515.5%  
Depreciation Rs m45115 2,964.5%   
Interest Rs m4910 514.7%   
Profit before tax Rs m5,47454 10,081.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,46010 15,207.3%   
Profit after tax Rs m4,01445 8,980.1%  
Gross profit margin %33.6-1.7 -1,953.5%  
Effective tax rate %26.717.7 150.9%   
Net profit margin %23.21.7 1,401.6%  
BALANCE SHEET DATA
Current assets Rs m7,6391,738 439.4%   
Current liabilities Rs m2,715545 498.4%   
Net working cap to sales %28.544.3 64.4%  
Current ratio x2.83.2 88.2%  
Inventory Days Days4348 89.2%  
Debtors Days Days794 1,827.6%  
Net fixed assets Rs m6,91412 58,099.2%   
Share capital Rs m17739 453.6%   
"Free" reserves Rs m11,4421,443 792.9%   
Net worth Rs m11,7211,482 790.9%   
Long term debt Rs m1490-   
Total assets Rs m14,8142,077 713.4%  
Interest coverage x112.96.7 1,681.7%   
Debt to equity ratio x00-  
Sales to assets ratio x1.21.3 89.8%   
Return on assets %27.42.6 1,050.8%  
Return on equity %34.23.0 1,135.5%  
Return on capital %46.54.3 1,080.9%  
Exports to sales %55.10-   
Imports to sales %6.024.5 24.6%   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038659 157.4%   
Fx inflow Rs m10,42217 60,591.9%   
Fx outflow Rs m1,678673 249.3%   
Net fx Rs m8,744-656 -1,332.9%   
CASH FLOW
From Operations Rs m3,26490 3,626.4%  
From Investments Rs m-2,093105 -2,000.9%  
From Financial Activity Rs m-1,186-14 8,409.2%  
Net Cashflow Rs m-15181 -8.2%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 3.8 40.8%  
FIIs % 7.6 0.1 7,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 21.2 80.2%  
Shareholders   20,968 4,783 438.4%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  DIVIS LABORATORIES  SANOFI INDIA  ALEMBIC PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; Healthcare & Metal Stocks Gain(09:30 am)

Asian stocks are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.17% while the Hang Seng is up 0.95%. The Nikkei 225 is trading up by 0.4%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 23, 2018 10:35 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - DR. DATSONS LABS COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS